Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 Equity-to-Asset is 0.40 as of Mar. 2025, which is at its 10-year median of 0.40. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 75.97% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avience Biomedicals's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ₹227.8 Mil. Avience Biomedicals's Total Assets for the quarter that ended in Mar. 2025 was ₹565.2 Mil.
Therefore, Avience Biomedicals's Equity to Asset Ratio for the quarter that ended in Mar. 2025 was 0.40.
The historical rank and industry rank for Avience Biomedicals's Equity-to-Asset or its related term are showing as below:
NSE:AVIENCE'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18 Med: 0.4 Max: 0.41
Current: 0.4
During the past 3 years, the highest Equity to Asset Ratio of Avience Biomedicals was 0.41. The lowest was 0.18. And the median was 0.40.
NSE:AVIENCE's Equity-to-Asset is ranked worse than 75.97% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs NSE:AVIENCE: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avience Biomedicals Equity-to-Asset Related Terms
Avience Biomedicals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Equity-to-Asset Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Equity-to-Asset
0.41
0.18
0.40
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Equity-to-Asset
0.41
0.18
0.40
NSE:AVIENCE vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Avience Biomedicals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avience Biomedicals's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals (NSE:AVIENCE) has a Equity-to-Asset of 0.40 as of Mar. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avience Biomedicals and its competitors. This is near median its historical median of 0.40. Over the past decade, Avience Biomedicals' Equity-to-Asset has ranged from 0.18 to 0.41. According to the industry distribution chart, Avience Biomedicals ranks #648 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 76%.
Is Avience Biomedicals' Equity-to-Asset too high?
Avience Biomedicals' current Equity-to-Asset of 0.40 is near median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.41. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Avience Biomedicals' value of 0.40 is 37.5% below this industry median. Based on the distribution chart, Avience Biomedicals ranks #648 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #648 out of 853 companies for Equity-to-Asset. This places Avience Biomedicals in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Avience Biomedicals' value of 0.40 is 37.5% below this benchmark. Historically, Avience Biomedicals' own Equity-to-Asset has ranged from 0.18 to 0.41 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.64, Avience Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current Equity-to-Asset of 0.40 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current Equity-to-Asset is 0.40, which is near median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Equity-to-Asset of 0.40. The current Equity-to-Asset is 0.40, which is near median its 10-year median of 0.40 and 37.5% below the Medical Devices & Instruments industry median of 0.64. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Equity-to-Asset is 0.40 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
